Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Sean Felix"'
Autor:
Zobair M. Younossi, Maria Stepanova, Brian Lam, Rebecca Cable, Sean Felix, Thomas Jeffers, Elena Younossi, Huong Pham, Manirath Srishord, Patrick Austin, Michael Estep, Kathy Terra, Carey Escheik, Leyla deAvila, Pegah Golabi, Andrej Kolacevski, Andrei Racila, Linda Henry, Lynn Gerber
Publikováno v:
Hepatology Communications, Vol 6, Iss 11, Pp 3062-3072 (2022)
The impact of the coronavirus disease 2019 (COVID‐19) pandemic among patients with chronic liver disease is unknown. Given the high prevalence of nonalcoholic fatty liver disease (NAFLD), we determined the predictors of mortality and hospital resou
Externí odkaz:
https://doaj.org/article/6dc06c8e1ef64e35b359559ab68fca45
Autor:
Zobair M. Younossi, Yusuf Yilmaz, Mohamed El‐Kassas, Ajay Duseja, Saeed Hamid, Gamal Esmat, Nahum Méndez‐Sánchez, Wah Kheong Chan, Ashwani K. Singal, Brian Lam, Sean Felix, Elena Younossi, Manisha Verma, Jillian K. Price, Fatema Nader, Issah Younossi, Andrei Racila, Maria Stepanova
Publikováno v:
Hepatology Communications, Vol 6, Iss 10, Pp 2860-2866 (2022)
Abstract Patients with preexisting chronic liver disease (CLD) may experience a substantial burden from both coronavirus 2019 (COVID‐19) infection and pandemic‐related life disruption. We assessed the impact of the COVID‐19 pandemic on patients
Externí odkaz:
https://doaj.org/article/84014429ef074574bdf4a6a0d13c9f95
Autor:
Maria Stepanova, Brian Lam, Elena Younossi, Sean Felix, Mariam Ziayee, Jillian Price, Huong Pham, Leyla de Avila, Kathy Terra, Patrick Austin, Thomas Jeffers, Carey Escheik, Pegah Golabi, Rebecca Cable, Manirath Srishord, Chapy Venkatesan, Linda Henry, Lynn Gerber, Zobair M. Younossi
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background COVID-19 outcomes among hospitalized patients may have changed due to new variants, therapies and vaccine availability. We assessed outcomes of adults hospitalized with COVID-19 from March 2020–February 2022. Methods Data were r
Externí odkaz:
https://doaj.org/article/c669c9b3af3e4a2286a0e2e024489b41
Autor:
Zobair M. Younossi, Maria Stepanova, Sean Felix, Thomas Jeffers, Elena Younossi, Zachary Goodman, Andrei Racila, Brian P. Lam, Linda Henry
Publikováno v:
Alimentary Pharmacology & Therapeutics. 57:1417-1422
Autor:
Zobair M. Younossi, Azza Karrar, Mariaelena Pierobon, Aybike Birerdinc, Maria Stepanova, Dinan Abdelatif, Zahra Younoszai, Thomas Jeffers, Sean Felix, Kianoush Jeiran, Alex Hodge, Weidong Zhou, Fanny Monge, Lakshmi Alaparthi, Vikas Chandhoke, Zachary D. Goodman, Emanuel F. Petricoin
Publikováno v:
BMC Medicine, Vol 16, Iss 1, Pp 1-13 (2018)
Abstract Background Non-alcoholic steatohepatitis (NASH) is among the leading causes of liver disease worldwide. It is increasingly recognized that the phenotype of NASH may involve a number of different pathways, of which each could become important
Externí odkaz:
https://doaj.org/article/7f7defeded5b4a4cbe23233ca72ace90
Autor:
Rohini Mehta, Gladys Shaw, Peter Masschelin, Sean Felix, Munkzhul Otgonsuren, Ancha Baranova, Zachary Goodman, Zobair Younossi
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0199294 (2018)
Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome and major cause of chronic liver disease in developed countries. Its prevalence is increasing in parallel with the prevalence of obesity and other components o
Externí odkaz:
https://doaj.org/article/43213bae2ba64c369051911b17d881b4
Autor:
ZOBAIR YOUNOSSI, SEAN FELIX, THOMAS JEFFERS, ELENA YOUNOSSI, FATEMA NADER, ANDREI RACILA, BRIAN P. LAM, MARIA STEPANOVA
Publikováno v:
Diabetes. 71
Background: Patients with nonalcoholic fatty liver disease (NAFLD) and fibrosis stage ≥ 2 (F2-F4) are at risk for adverse outcomes and considered to be candidates for clinical trials. We aimed to use two NITs combined to rule in and rule out fibros
Autor:
Daisong Tan, Brian Lam, Zachary Goodman, Azza Karrar, Ali Moosvi, Sean Felix, Sohailla Noor, Donna Esmaeili, Lakshmi Alaparthi, Irfan Ali, Dinan Abdelatif, Mohamad Houry, Siddharth Hariharan, Munkhzul Otgonsuren, Zobair M. Younossi, Bijal Rajput
Publikováno v:
Hepatology Communications
Major histocompatibility complex class I‐related chain A (MICA) is a highly polymorphic gene that modulates immune surveillance by binding to its receptor on natural killer cells, and its genetic polymorphisms have been associated with chronic immu
Autor:
Huong Pham, Brian Lam, Pegah Golabi, Linda Henry, Zobair M. Younossi, Andrei Racila, Sean Felix, Kathy L. Terra, Maria Stepanova, Manirath K. Srishord, Elena Younossi, Lynn H. Gerber, Michael Estep, Leyla de Avila, Patrick Austin, Andrej Kolacevski, Carey Escheik, Thomas Jeffers, Rebecca Cable
Publikováno v:
Hepatology Communications
The impact of the coronavirus disease 2019 (COVID‐19) pandemic among patients with chronic liver disease is unknown. Given the high prevalence of nonalcoholic fatty liver disease (NAFLD), we determined the predictors of mortality and hospital resou
Autor:
Maria Stepanova, Sean Felix, Thomas Jeffers, Elena Younossi, Brian Lam, Linda Henry, Zobair Younossi
Publikováno v:
Journal of Hepatology. 77:S429